199 related articles for article (PubMed ID: 17541741)
41. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
42. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.
Bonanni B; Macis D; Maisonneuve P; Johansson HA; Gucciardo G; Oliviero P; Travaglini R; Muraca MG; Rotmensz N; Veronesi U; Decensi AU
J Clin Oncol; 2006 Aug; 24(22):3708-9; author reply 3709. PubMed ID: 16877740
[No Abstract] [Full Text] [Related]
43. Hot flashes in breast cancer survivors.
Hoda D; Perez DG; Loprinzi CL
Breast J; 2003; 9(5):431-8. PubMed ID: 12968972
[TBL] [Abstract][Full Text] [Related]
44. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer.
Fenlon DR; Corner JL; Haviland JS
J Pain Symptom Manage; 2008 Apr; 35(4):397-405. PubMed ID: 18359433
[TBL] [Abstract][Full Text] [Related]
45. Dietary factors and vasomotor symptoms in breast cancer survivors: the WHEL Study.
Gold EB; Flatt SW; Pierce JP; Bardwell WA; Hajek RA; Newman VA; Rock CL; Stefanick ML
Menopause; 2006; 13(3):423-33. PubMed ID: 16735939
[TBL] [Abstract][Full Text] [Related]
46. Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival.
Ertz-Archambault NM; Rogoff LB; Kosiorek HE; Ernst BJ; Anderson KS; Pockaj BA; Gray RJ; Northfelt DW
Support Care Cancer; 2020 May; 28(5):2139-2143. PubMed ID: 31402403
[TBL] [Abstract][Full Text] [Related]
47. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
Gallicchio L; Lord G; Tkaczuk K; Danton M; Lewis LM; Lim CK; Flaws JA
Breast Cancer Res Treat; 2004 May; 85(1):89-97. PubMed ID: 15039600
[TBL] [Abstract][Full Text] [Related]
48. Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?
Lee CI; Fox P; Balakrishnar B; Balleine RL; Gao B; Provan P; Coulter S; Liddle C; Hui R; Wong M; Gurney H; Wilcken N
Breast; 2019 Aug; 46():52-57. PubMed ID: 31082762
[TBL] [Abstract][Full Text] [Related]
49. Breast cancer and duration of tamoxifen.
Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
[TBL] [Abstract][Full Text] [Related]
50. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
Jin Y; Hayes DF; Li L; Robarge JD; Skaar TC; Philips S; Nguyen A; Schott A; Hayden J; Lemler S; Storniolo AM; Flockhart DA; Stearns V
J Clin Oncol; 2008 Dec; 26(36):5849-54. PubMed ID: 19018086
[TBL] [Abstract][Full Text] [Related]
51. Tamoxifen as an ergogenic agent in women body builders.
Seehusen DA; Glorioso JE
Clin J Sport Med; 2002 Sep; 12(5):313-4. PubMed ID: 12394205
[No Abstract] [Full Text] [Related]
52. Patient- versus physician-reported outcomes in a low-dose tamoxifen trial in noninvasive breast cancer.
Buttiron Webber T; Marra D; Puntoni M; Giuliano S; Briata IM; Cevasco I; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Provinciali N; Lazzeroni M; Bonanni B; DeCensi A
Breast J; 2021 Nov; 27(11):817-823. PubMed ID: 34626060
[TBL] [Abstract][Full Text] [Related]
53. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up.
Haest K; Kumar A; Van Calster B; Leunen K; Smeets A; Amant F; Berteloot P; Wildiers H; Paridaens R; Van Limbergen E; Weltens C; Janssen H; Peeters S; Menten J; Vergote I; Morlion B; Verhaeghe J; Christiaens MR; Neven P
Ann Oncol; 2012 Jun; 23(6):1449-54. PubMed ID: 22039079
[TBL] [Abstract][Full Text] [Related]
54. Breast cancer and antidepressant use.
Andrade C
J Clin Psychiatry; 2012 Sep; 73(9):e1156-7. PubMed ID: 23059156
[No Abstract] [Full Text] [Related]
55. Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes.
Emond JA; Patterson RE; Natarajan L; Laughlin GA; Gold EB; Pierce JP
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):939-45. PubMed ID: 21415358
[TBL] [Abstract][Full Text] [Related]
56. Tamoxifen in breast cancer: symptom reporting.
Arnold BJ; Cumming CE; Lees AW; Handman MD; Cumming DC; Urion C
Breast J; 2001; 7(2):97-100. PubMed ID: 11328315
[TBL] [Abstract][Full Text] [Related]
57. Acupuncture in the control of vasomotor symptoms caused by tamoxifen.
Towlerton G; Filshie J; O'Brien M; Duncan A
Palliat Med; 1999 Sep; 13(5):445. PubMed ID: 10659122
[No Abstract] [Full Text] [Related]
58. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors.
Caan BJ; Emond JA; Su HI; Patterson RE; Flatt SW; Gold EB; Newman VA; Rock CL; Thomson CA; Pierce JP
J Clin Oncol; 2012 May; 30(13):1492-7. PubMed ID: 22430275
[TBL] [Abstract][Full Text] [Related]
59. Oxybutynin for hot flashes in women with breast cancer.
Med Lett Drugs Ther; 2019 Feb; 61(1566):30-31. PubMed ID: 30845103
[No Abstract] [Full Text] [Related]
60. Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.
Carpenter JS; Yu M; Wu J; Von Ah D; Milata J; Otte JL; Johns S; Schneider B; Storniolo AM; Salomon R; Desta Z; Cao D; Jin Y; Philips S; Skaar TC
Menopause; 2009; 16(4):644-52. PubMed ID: 19265726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
